Tamoxifen-induced thrombocytopenia

Am J Clin Oncol. 1999 Oct;22(5):529-32. doi: 10.1097/00000421-199910000-00022.

Abstract

Thrombocytopenia (platelet count < 100,000/microl) is a rare side effect of tamoxifen (Nolvadex). We report a case of thrombocytopenia that developed 6 months after tamoxifen was given as an adjuvant treatment for breast cancer. The patient received no concurrent cytotoxic chemotherapy or radiation therapy. The thrombocytopenia resolved after the tamoxifen was stopped, reappeared promptly when the tamoxifen was restarted, and resolved again after the second withdrawal, at which time anastrozole (Arimidex) was substituted for the tamoxifen. The patient's platelet count remained normal for more than 6 months thereafter.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Antineoplastic Agents, Hormonal / adverse effects*
  • Breast Neoplasms / drug therapy*
  • Clinical Trials as Topic
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Incidence
  • Middle Aged
  • Tamoxifen / adverse effects*
  • Thrombocytopenia / chemically induced*
  • Thrombocytopenia / epidemiology

Substances

  • Antineoplastic Agents, Hormonal
  • Tamoxifen